Similar trends were observed in our in-house cohort of 96 prostate cancer patients, where higher LTFe levels correlated with favorable clinical outcomes, including reduced risk of BCR, lower Gleason scores and earlier T stages (Fig. 1p–r). This evidence concerns the gene BCR and prostate cancer.